Abstract
The aim of this study was to determine the treatment preferences (adjuvant goserelin or cyclophosphamide, methotrexate and fluorouracil (CMF) chemotherapy) of healthy premenopausal women should they hypothetically develop oestrogen-receptor (ER) positive early breast cancer. Two hundred pre or peri-menopausal women read two scenarios describing goserelin or chemotherapy. Information included: How and where treatments were administered, side-effects, their likely persistence and impact on fertility. Women stated their unprompted initial and final preferences with reasons for the choices made. Respondents showed an overwhelming preference for goserelin. 156 (78%) women favoured goserelin, 22 (11%) chemotherapy and 22 (11%) remained undecided (P
| Original language | English |
|---|---|
| Pages (from-to) | 2403-10 |
| Number of pages | 8 |
| Journal | European journal of cancer (Oxford, England : 1990) |
| Volume | 40 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - Nov 2004 |
Keywords / Materials (for Non-textual outputs)
- Activities of Daily Living
- Adult
- Antineoplastic Agents, Hormonal
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Cyclophosphamide
- Female
- Fertility
- Fluorouracil
- Goserelin
- Humans
- Interpersonal Relations
- Methotrexate
- Middle Aged
- Patient Satisfaction
- Premenopause
- Time Factors
Fingerprint
Dive into the research topics of 'Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver